ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Celgene’s Pomalyst secures breakthrough designation pharmaceutical-technology
May 16, 2019The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to Celgene’s Pomalyst (pomalidomide) in HIV-positive and HIV-negative Kaposi sarcoma.
Pharma Sources Insight January 2025
